You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
啟明醫療-B(02500.HK)委任Martin B. Leon教授擔任RDN創新器械全球首要研究者
格隆匯 07-27 16:38

格隆匯7月27日丨啟明醫療-B(02500.HK)宣佈,已委任Martin B. Leon教授為控股子公司Renaly開發的新一代去腎交感神經術("RDN")創新器械的全球首要研究者("PI")。

Martin B. Leon教授是公司全球諮詢委員會成員,亦是美國哥倫比亞大學醫學中心醫學教授,他同時擔任哥倫比亞介入血管治療中心主任、心臟導管實驗室主任,以及哥倫比亞心臟瓣膜中心執行委員會主任。此外,他還是全球經導管心血管治療大會(“”TCT“”)創始人和主席。在RDN領域,Martin教授及其團隊已擔任多個創新器械的臨牀試驗PI,如美敦力的Symplicity Spyral腎臟去神經系統和Re Cor Medical的Paradise超聲波去神經系統。這兩款產品均在2020年獲得美國食品藥品監督管理局(“”FDA“”)頒發的“”突破性設備“”稱號。

Renaly所開發的新一代RDN器械,其獨有的雙模態超聲技術平台,可實現具備實時監測功能的非接觸性連續消融治療,在進行精準高效消融的同時顯着降低由於消融不可控帶來的諸如神經消融不充分或血管損傷等問題的發生,可促使治療結果可預測,手術過程簡單化,最終提升手術的安全性和有效性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account